Tocagen, a US-based clinical stage biopharmaceutical company developing gene therapy products, has named Asha Das as Vice President of Clinical Development and Medical Affairs.
Prior to joining Tocagen Das held positions of increasing responsibility at Genentech, including leading activities related to the approval and launch of Avastin in recurrent glioblastoma, expansion into platinum-resistant ovarian cancer and metastatic cervical cancer as well as clinical activities related to PD-L1.
'As we prepare to begin enrolment in Toca 5, our registrational trial investigating Toca 511 and Toca FC in patients with recurrent glioblastoma or anaplastic astrocytoma, we have further strengthened our clinical leadership team,' said Jamey Skillings, Chief Medical Officer of Tocagen. 'Our clinical group now boasts three oncologists, and their perspectives, particularly Asha's insights from her work expanding Avastin into use in recurrent glioblastoma, will be extremely valuable as we transition into late-stage development.'
Prior to Genentech, Dr. Das was an Associate Director at Eisai, focused on clinical activities related to the oncology therapeutics HALAVEN and LENVIMA. Previously, she led the neuro-oncology programme at Cedars-Sinai in Los Angeles.
